Asset
LATOZINEMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03636204 | phase1 | completed | 2018-09-14 | 2019-12-31 | Alector Inc. | A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation |
| NCT05053035 | phase2 | terminated | 2021-09-02 | 2022-10-28 | Alector Inc. | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS |
| NCT03987295 | phase2 | completed | 2019-09-27 | 2024-06-05 | Alector Inc. | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) |
| NCT04374136 | phase3 | terminated | 2020-07-23 | 2025-09-01 | Alector Inc. | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) |
FDA applications (0)
This company has no applications containing this asset.